Is Evolus, Inc. overvalued or undervalued?

As of 12 August 2019, the valuation grade for Evolus, Inc. moved from does not qualify to risky, indicating a significant shift in its financial standing. The company appears to be overvalued, particularly given its troubling financial metrics, including a Price to Book Value of -98.02, an EV to EBIT of -19.61, and an EV to EBITDA of -23.65. These ratios suggest that the company's valuation is not supported by its financial performance.
In comparison to its peers, Evolus, Inc. has a P/E ratio of -8.2365, while PetIQ, Inc. holds a fair valuation with a P/E ratio of 27.1022, highlighting a stark contrast in market perception. Additionally, Repare Therapeutics, Inc. does not qualify for a valuation, further emphasizing the challenges Evolus faces in its industry. Over the past year, Evolus has underperformed significantly, with a stock return of -60.42% compared to the S&P 500's return of 17.14%, reinforcing the notion that the stock is overvalued in its current state.